AAPL333.02+3.62 (+1.10%) ▲|ABBV261.59-1.70 (-0.65%) ▼|ABT98.83-2.12 (-2.10%) ▼|ACN183.37+6.25 (+3.53%) ▲|ADBE239.94+6.77 (+2.90%) ▲|AMAT511.38-0.63 (-0.12%) ▼|AMD611.76+4.19 (+0.69%) ▲|AMGN421.51-2.13 (-0.50%) ▼|AMT163.69-1.87 (-1.13%) ▼|AMZN249.15+2.48 (+1.01%) ▲|AVGO351.19-3.91 (-1.10%) ▼|AXP304.10-1.30 (-0.43%) ▼|BA186.05-1.63 (-0.87%) ▼|BAC54.43-0.53 (-0.96%) ▼|BKNG162.91+0.57 (+0.35%) ▲|BLK1,058.29-9.65 (-0.90%) ▼|BMY62.40-0.46 (-0.73%) ▼|BNY144.63-2.35 (-1.60%) ▼|BRK-B497.95-4.40 (-0.88%) ▼|C129.48-1.32 (-1.01%) ▼|CAT810.79-15.85 (-1.92%) ▼|CL85.32-1.14 (-1.32%) ▼|CMCSA21.76+0.16 (+0.74%) ▲|COF193.07-3.39 (-1.73%) ▼|COP125.15-0.29 (-0.23%) ▼|COST910.34-14.25 (-1.54%) ▼|CRM229.57+4.26 (+1.89%) ▲|CSCO107.63+0.69 (+0.65%) ▲|CVS85.69-1.41 (-1.62%) ▼|CVX204.21-0.17 (-0.08%) ▼|DE671.55-7.33 (-1.08%) ▼|DHR221.55-4.16 (-1.84%) ▼|DIS104.90-0.51 (-0.48%) ▼|DUK114.01-0.20 (-0.18%) ▼|EMR155.10-2.14 (-1.36%) ▼|FDX285.09-2.38 (-0.83%) ▼|GD331.83-0.51 (-0.15%) ▼|GE312.29-5.60 (-1.76%) ▼|GEV950.49-12.00 (-1.25%) ▼|GILD149.05-2.23 (-1.47%) ▼|GM77.00-3.47 (-4.31%) ▼|GOOG340.74+3.42 (+1.01%) ▲|GOOGL344.08+3.16 (+0.93%) ▲|GS900.36-15.88 (-1.73%) ▼|HD284.49-3.55 (-1.23%) ▼|HON210.94+0.81 (+0.39%) ▲|IBM219.93-0.06 (-0.03%) ▼|INTC120.23+4.30 (+3.71%) ▲|INTU275.71+7.68 (+2.87%) ▲|ISRG406.63-5.55 (-1.35%) ▼|JNJ264.74-2.83 (-1.06%) ▼|JPM330.83-4.15 (-1.24%) ▼|KO86.08-0.76 (-0.88%) ▼|LIN474.65+1.28 (+0.27%) ▲|LLY1,157.08-27.55 (-2.33%) ▼|LMT509.25-2.96 (-0.58%) ▼|LOW184.29-2.97 (-1.59%) ▼|LRCX328.51+4.65 (+1.44%) ▲|MA551.47-12.11 (-2.15%) ▼|MCD230.94-3.04 (-1.30%) ▼|MDLZ57.82-0.98 (-1.67%) ▼|MDT86.29-0.80 (-0.92%) ▼|META725.18-13.61 (-1.84%) ▼|MMM164.15-4.34 (-2.58%) ▼|MO67.34-1.38 (-2.01%) ▼|MRK145.31-3.97 (-2.66%) ▼|MS188.08-4.68 (-2.43%) ▼|MSFT512.90+3.94 (+0.77%) ▲|MU1,065.11+0.03 (+0.00%) ▲|NEE75.74-0.15 (-0.20%) ▼|NFLX69.58-0.72 (-1.02%) ▼|NKE35.40-0.44 (-1.23%) ▼|NOW134.01+4.07 (+3.13%) ▲|NVDA228.38+1.17 (+0.51%) ▲|ORCL137.30-0.49 (-0.36%) ▼|PEP126.72-1.97 (-1.53%) ▼|PFE28.52-0.20 (-0.70%) ▼|PG145.28-3.04 (-2.05%) ▼|PLTR187.05+0.08 (+0.04%) ▲|PM190.82-3.08 (-1.59%) ▼|QCOM184.04-0.06 (-0.03%) ▼|RTX185.65-1.29 (-0.69%) ▼|SBUX93.96-1.47 (-1.54%) ▼|SCHW97.74-1.36 (-1.37%) ▼|SO82.89-0.56 (-0.67%) ▼|SPG200.76-3.52 (-1.72%) ▼|T24.40-0.08 (-0.33%) ▼|TMO675.05-4.56 (-0.67%) ▼|TMUS163.08+0.10 (+0.06%) ▲|TSLA354.81+1.97 (+0.56%) ▲|TXN280.09-1.60 (-0.57%) ▼|UBER68.51-0.85 (-1.23%) ▼|UNH367.08-7.86 (-2.10%) ▼|UNP272.13-2.02 (-0.74%) ▼|UPS93.44-0.49 (-0.52%) ▼|USB57.76+0.16 (+0.28%) ▲|V359.33-6.55 (-1.79%) ▼|VZ45.87-0.11 (-0.24%) ▼|WFC80.05-0.43 (-0.53%) ▼|WMT103.92-2.88 (-2.70%) ▼|XOM162.75+1.40 (+0.87%) ▲|AAPL333.02+3.62 (+1.10%) ▲|ABBV261.59-1.70 (-0.65%) ▼|ABT98.83-2.12 (-2.10%) ▼|ACN183.37+6.25 (+3.53%) ▲|ADBE239.94+6.77 (+2.90%) ▲|AMAT511.38-0.63 (-0.12%) ▼|AMD611.76+4.19 (+0.69%) ▲|AMGN421.51-2.13 (-0.50%) ▼|AMT163.69-1.87 (-1.13%) ▼|AMZN249.15+2.48 (+1.01%) ▲|AVGO351.19-3.91 (-1.10%) ▼|AXP304.10-1.30 (-0.43%) ▼|BA186.05-1.63 (-0.87%) ▼|BAC54.43-0.53 (-0.96%) ▼|BKNG162.91+0.57 (+0.35%) ▲|BLK1,058.29-9.65 (-0.90%) ▼|BMY62.40-0.46 (-0.73%) ▼|BNY144.63-2.35 (-1.60%) ▼|BRK-B497.95-4.40 (-0.88%) ▼|C129.48-1.32 (-1.01%) ▼|CAT810.79-15.85 (-1.92%) ▼|CL85.32-1.14 (-1.32%) ▼|CMCSA21.76+0.16 (+0.74%) ▲|COF193.07-3.39 (-1.73%) ▼|COP125.15-0.29 (-0.23%) ▼|COST910.34-14.25 (-1.54%) ▼|CRM229.57+4.26 (+1.89%) ▲|CSCO107.63+0.69 (+0.65%) ▲|CVS85.69-1.41 (-1.62%) ▼|CVX204.21-0.17 (-0.08%) ▼|DE671.55-7.33 (-1.08%) ▼|DHR221.55-4.16 (-1.84%) ▼|DIS104.90-0.51 (-0.48%) ▼|DUK114.01-0.20 (-0.18%) ▼|EMR155.10-2.14 (-1.36%) ▼|FDX285.09-2.38 (-0.83%) ▼|GD331.83-0.51 (-0.15%) ▼|GE312.29-5.60 (-1.76%) ▼|GEV950.49-12.00 (-1.25%) ▼|GILD149.05-2.23 (-1.47%) ▼|GM77.00-3.47 (-4.31%) ▼|GOOG340.74+3.42 (+1.01%) ▲|GOOGL344.08+3.16 (+0.93%) ▲|GS900.36-15.88 (-1.73%) ▼|HD284.49-3.55 (-1.23%) ▼|HON210.94+0.81 (+0.39%) ▲|IBM219.93-0.06 (-0.03%) ▼|INTC120.23+4.30 (+3.71%) ▲|INTU275.71+7.68 (+2.87%) ▲|ISRG406.63-5.55 (-1.35%) ▼|JNJ264.74-2.83 (-1.06%) ▼|JPM330.83-4.15 (-1.24%) ▼|KO86.08-0.76 (-0.88%) ▼|LIN474.65+1.28 (+0.27%) ▲|LLY1,157.08-27.55 (-2.33%) ▼|LMT509.25-2.96 (-0.58%) ▼|LOW184.29-2.97 (-1.59%) ▼|LRCX328.51+4.65 (+1.44%) ▲|MA551.47-12.11 (-2.15%) ▼|MCD230.94-3.04 (-1.30%) ▼|MDLZ57.82-0.98 (-1.67%) ▼|MDT86.29-0.80 (-0.92%) ▼|META725.18-13.61 (-1.84%) ▼|MMM164.15-4.34 (-2.58%) ▼|MO67.34-1.38 (-2.01%) ▼|MRK145.31-3.97 (-2.66%) ▼|MS188.08-4.68 (-2.43%) ▼|MSFT512.90+3.94 (+0.77%) ▲|MU1,065.11+0.03 (+0.00%) ▲|NEE75.74-0.15 (-0.20%) ▼|NFLX69.58-0.72 (-1.02%) ▼|NKE35.40-0.44 (-1.23%) ▼|NOW134.01+4.07 (+3.13%) ▲|NVDA228.38+1.17 (+0.51%) ▲|ORCL137.30-0.49 (-0.36%) ▼|PEP126.72-1.97 (-1.53%) ▼|PFE28.52-0.20 (-0.70%) ▼|PG145.28-3.04 (-2.05%) ▼|PLTR187.05+0.08 (+0.04%) ▲|PM190.82-3.08 (-1.59%) ▼|QCOM184.04-0.06 (-0.03%) ▼|RTX185.65-1.29 (-0.69%) ▼|SBUX93.96-1.47 (-1.54%) ▼|SCHW97.74-1.36 (-1.37%) ▼|SO82.89-0.56 (-0.67%) ▼|SPG200.76-3.52 (-1.72%) ▼|T24.40-0.08 (-0.33%) ▼|TMO675.05-4.56 (-0.67%) ▼|TMUS163.08+0.10 (+0.06%) ▲|TSLA354.81+1.97 (+0.56%) ▲|TXN280.09-1.60 (-0.57%) ▼|UBER68.51-0.85 (-1.23%) ▼|UNH367.08-7.86 (-2.10%) ▼|UNP272.13-2.02 (-0.74%) ▼|UPS93.44-0.49 (-0.52%) ▼|USB57.76+0.16 (+0.28%) ▲|V359.33-6.55 (-1.79%) ▼|VZ45.87-0.11 (-0.24%) ▼|WFC80.05-0.43 (-0.53%) ▼|WMT103.92-2.88 (-2.70%) ▼|XOM162.75+1.40 (+0.87%) ▲|
19 C
New York
Thursday, October 1, 2026

Tag: time

newssourceFORcompanyinformationcontent1releasesmarket

EHA 2025 | Multiple Studies Report Encouraging Data of Olverembatinib in Ph+ ALL

ROCKVILLE, Md. and SUZHOU, China, June 15, 2025 (GLOBE NEWSWIRE) -- Ascentage Pharma (NASDAQ: AAPG; HKEX: 6855), a global biopharmaceutical company dedicated to addressing unmet medical needs in cancers, announced that results from 13 studies of its core assets, including the novel drug olverembatinib (HQP1351) and the investigational EED inhibitor APG-5918, have been reported at the 2025 European Hematology Association (EHA) Annual Congress.

Samsung Biologics launches drug screening services, Samsung Organoids

Samsung Organoids to provide data-driven analysis of candidate moleculesSamsung Biologics expands service scope to include preclinical researchINCHEON, South Korea, June 15, 2025 /PRNewswire/ --...

Coding Hype Threatens Engineers — Again

On a screen in Kirkland, Washington, Steve Yegge, an old hand in software engineering, watches as AI churns out code like a machine on...

Statement from the Alzheimer’s Drug Discovery Foundation on the Passing of ADDF Co-Founder and Co-Chairman Leonard A. Lauder

The Lauder Family's Vision and Catalytic Funding Through the ADDF Helped Seed and Transform the Alzheimer's Research Landscape NEW YORK, June 15, 2025 /PRNewswire/ --...

Ahead of the $3 XRP Era, PFMCrypto Launches 2-Day XRP Mining Promotion, $1 Million Giveaway Sparks Community Excitement

As XRP appears poised to surge to $3 in June, leading XRP mining platform PFMCrypto has launched a 48-hour exclusive XRP mining promotion, giving away $1 million USD in rewards to its global user base 
As XRP appears poised to surge to $3 in June, leading XRP mining platform PFMCrypto has launched a 48-hour exclusive XRP mining promotion, giving away $1 million USD in rewards to its global user base

IBTA INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Ibotta, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit

NEW YORK, June 15, 2025 (GLOBE NEWSWIRE) -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Ibotta, Inc. (“Ibotta” or “the Company”) (NYSE: IBTA) and certain of its officers.

Announcement regarding the governance of Renault Group

Announcement regarding the governance
of Renault Group

China Trade ‘Deal’: U.S. Masterclass in Running Circles

In the grand theater of global economics, the U.S. and China have once again graced us with a riveting episode of "Let's Pretend We're...

HAPPY FATHER’S DAY! and $HAREHOLDER ALERT: Class Action Attorney Juan Monteverde Investigates the Merger of Atai Life Sciences N.V. (NASDAQ: ATAI)

NEW YORK, June 15, 2025 (GLOBE NEWSWIRE) --

Class Action Attorney Juan Monteverde with Monteverde & Associates PC (the “M&A Class Action Firm”), has recovered millions of dollars for shareholders and is recognized as a Top 50 Firm in the 2024 ISS Securities Class Action Services Report. The firm is headquartered at the Empire State Building in New York City and is investigating Atai Life Sciences N.V. (NASDAQ: ATAI) related to the acquisition of Beckley Psytech Limited. Is it a fair deal?

Levi & Korsinsky Announces the Filing of a Securities Class Action on Behalf of Iovance Biotherapeutics, Inc.(IOVA) Shareholders

NEW YORK, June 15, 2025 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in Iovance Biotherapeutics, Inc. ("Iovance" or the "Company") (NASDAQ: IOVA) of a class action securities lawsuit.

Shinning in the Lion City: Intangible Cultural Heritage Markets and Artistic Masterpieces Made a Brilliant Appearance at the “Chongqing Week in Singapore”

SINGAPORE, June 15, 2025 /PRNewswire/ -- A news report from iChongqing: To celebrate the 35th anniversary of the establishment of diplomatic relations between China and...

CAR FINAL DEADLINE: ROSEN, TRUSTED INVESTOR COUNSEL, Encourages Avis Budget Group, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important...

NEW YORK, June 15, 2025 (GLOBE NEWSWIRE) --

WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Avis Budget Group, Inc. (NASDAQ: CAR) between February 16, 2024 and February 10, 2025, both dates inclusive (the “Class Period”), of the important June 24, 2025 lead plaintiff deadline.

Press Release: EAACI: Dupixent demonstrated superiority over Xolair (omalizumab) in chronic rhinosinusitis with nasal polyps in patients with coexisting asthma in first-ever presented phase...

EAACI: Dupixent demonstrated superiority over Xolair (omalizumab) in chronic rhinosinusitis with nasal polyps in patients with coexisting asthma in first-ever presented phase 4 head-to-head respiratory study

Dupixent® (dupilumab) Demonstrated Superiority Over Xolair® (Omalizumab) in Chronic Rhinosinusitis with Nasal Polyps (CRSwNP) in Patients with Coexisting Asthma in First-ever Presented Phase 4...

New late-breaking data at EAACI showed Dupixent outperformed Xolair across all primary and secondary efficacy endpoints of CRSwNP and in all asthma-related endpoints

- A word from our sponsors -

spot_img

Newsletter Signup

Name(Required)
Email(Required)
Privacy(Required)
This field is for validation purposes and should be left unchanged.
HomeTagsTime

Explore

Press Releases

News & Opinion

Living

Others

Follow us

© Copyright 2025. BusinessPressWire® / 14 Wall Street New York City NY 10005 +1 888-502-0266 / Disclaimers